• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief


Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Pokaż więcej ( Stron)

Pełen tekst



The Voice of the Editor-in-Chief

The new issue of “Clinical Diabetology” is released at the moment when the holiday comes to an end and we return to daily clinical work, and many of us also to our scientific activity. At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this conference is the publication of third joint consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) on the management of patients with diabetes (ADA/EASD Gu- idance on Diabetes). These guidelines were announced before the summer, during the Congress of American Diabetes Association (ADA) in Orlando, USA. At that time, the practical aspect of emerging guidelines was emphasized, especially with regard to the choice of treatment strategy for type 2 diabetes, including recommendations not only how to establish the indi- vidual goal of therapy, but rather how to achieve it.

Metformin remains invariably the first choice therapy, but GLP-1 receptor agonists and SGLT2 inhibitors will be recommended, in specific situations, as second- -line drugs, before initiation of insulin therapy, taking into account economic barriers to the proposed treat- ment strategy.

Considering our diverse group of readers, we include in each issue of “Clinical Diabetology”, both

articles focused on clinical practice and papers with more scientific approach. This issue contains a very interesting paper assessing the knowledge about dia- betes among healthy people. It should be stressed that each IDF report on the incidence of diabetes contains more and more alarming information, and therefore there is a huge need to raise public awareness about type 2 diabetes, especially among people with risk factors. While the causes leading to the development of type 2 diabetes, including the role of genetic factors, are quite well known, the exact mechanism of the development of type 1 diabetes is still unclear. Worth reading is the original article that shed some light on this topic — the authors assess the expression of micro RNA (miR-652-5p) in patients with newly diagnosed type 1 diabetes. Another important problem related to diabetes, both type 1 and type 2, is the fact that in many patients the disease leads inevitably to the deve- lopment of vascular complications and diagnostic and prognostic markers are still being sought. In presented issue two relevant papers can be found, an original one and a review one, which evaluate the role of pentraxin 3 in development of atherosclerosis and its relation to diabetic retinopathy.

As usual, I thank everyone for submitting so many valuable papers and encourage you to further coope- ration.


Prof. Janusz Gumprecht

Dear Colleagues,



Powiązane dokumenty

Przekazywał nam też hoj- nie swoje wiadomości, choć byliśmy w wieku, kiedy na ogół nie docenia się wielu skarbów pchających się w ręce.. Na szczęście zapamiętałam zdradzone

Professor Janusz Gumprecht has excellently developed the journal — it appears regularly, contains more and more papers from outside Poland, is included in the Web of Science

Just before the publication of this issue of “Cli- nical Diabetology”, the largest diabetes meeting in the world — 79 th Scientific Sessions of the American Diabetes

Although more than 3,500 years have passed since the first description of the symptoms of diabetes in the Egyptian papyrus dated to around 1550 BC, diabetes is still

differences in the frequency, causes and duration of hospitalization of children with diabetes in different regions of Poland, which implies the need to ensure uniform access

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would

Considering the above, I would like to draw your attention to two of many interesting articles published in the last issue of Clinical Diabetology: the paper presenting

In accordance with other diabetic organizations (the American Diabetes Association — ADA, the National Institute for Health and Care Excellence — NICE), glycaemic goals has

Here, it should be mentioned that also the LEADER trial, that assessed cardiovascular safety of one of GLP-1 agonists, liraglutide, in the population of type 2 diabetes

Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes

The conference brought together a group of distinguished lecturers and almost 500 participants — physicians dealing in their everyday practice with carbohydrate

At the same time, we intend to continue the educational function of the journal and we do not want to hinder the access to its content for the readers; therefore, we decided

This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to

Walny Zjazd Członków Polskiego Towarzystwa Diabetologicznego odbył się w Łodzi 23 maja 2003 roku podczas IX Zjazdu PTD.. Zebraniu

Przedstawiono również wyniki badań GetGo- al Duo 1 i GetGoal-L2, które wykazały, że lik- sysenatyd w skojarzeniu z insuliną bazową i doustnymi lekami przeciwcukrzycowymi

„Rodzina w systemie wsparcia społecznego i pomocy osobom z problemem alkoholowym”, zorganizowana przez Pracownię Pedagogiki Specjalnej, w ramach realizowanego